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Abstract
The paper continues the series of publications from the International Nuclear Workers Study 
cohort (INWORKS) that comprises 308,297 workers from France, the United Kingdom and the 
United States, providing 8.2 million person-years of observation from a combined follow-up 
period (at earliest 1944 to at latest 2005). These workers' external radiation exposures were 
primarily to photons, resulting in an estimated average career absorbed dose to the colon of 17.4 
milligray. The association between cumulative ionizing radiation dose and cancer mortality was 
evaluated in general relative risk models that describe modification of the excess relative risk 
(ERR) per gray (Gy) by time since exposure and age at exposure. Methods analogous to a nested-
case control study using conditional logistic regression of sampled risks sets were used. Outcomes 
included: all solid cancers, lung cancer, leukemias excluding chronic lymphocytic, acute myeloid 
leukemia, chronic myeloid leukemia, multiple myeloma, Hodgkin lymphoma, and non-Hodgkin 
lymphoma.
Significant risk heterogeneity was evident in chronic myeloid leukemia with time since exposure, 
where we observed increased ERR per Gy estimates shortly after exposure (2-10 year) and again 
later (20-30 years). We observed delayed effects for acute myeloid leukemia although estimates 
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were not statistically significant. Solid cancer excess risk was restricted to exposure at age 35+ 
years and also diminished for exposure 30 years prior to attained age. Persistent or late effects 
suggest additional follow-up may inform on lifetime risks. However, cautious interpretation of 
results is needed due to analytical limitations and a lack of confirmatory results from other studies.
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Introduction
Exposure to ionizing radiation, a known human carcinogen, is unavoidable.1 Ubiquitous 
natural and man-made environmental sources account for about one-half of the average 
annual per capita effective dose in developed countries. The remaining dose stems primarily 
from radiation used in diagnostic and therapeutic medicine.2 Moreover, the trend in 
population dose is increasing as a consequence of a proliferation in radiologic and nuclear 
medicine procedures in recent years. In the United States of America (USA), the annual per 
capita effective dose has risen two-fold in the last 25 years from a concurrent 10-fold 
increase in diagnostic and interventional radiologic examinations and a 2.5-fold increase in 
nuclear medicine procedures.3
In addition to environmental and medical exposures, millions of workers worldwide are 
exposed in the course of their employment in many occupational settings, such as 
healthcare, research, military, general industry and commercial nuclear power.2 Protection 
standards adopted to mitigate health risks are based on our current understanding of the 
relation between ionizing radiation and cancer, which relies heavily on studies of acutely 
exposed populations, such as the Japanese atomic bomb survivors or radiation therapy 
patients who received highly fractionated doses.4 Yet exposure conditions among these 
populations differ greatly from that of nuclear workers, whose radiation dose accrues from 
protracted low dose and low dose rate exposures. Clearly, direct information from 
occupational studies promises better estimates of nuclear worker cancer risks; however, 
occupational studies have lacked sufficient precision to project population-based risks.5
Recent studies have pooled information from several occupational sources to increase study 
size. The International Agency for Research on Cancer (IARC) has led efforts to conduct 
pooled studies of nuclear workers from several countries.6-8 The most recent IARC study, 
the International Nuclear Workers Study (INWORKS), involves a consortium from France, 
the United Kingdom (UK) and the USA who are examining mortality patterns in about 
300,000 nuclear workers.8 Initial examinations of the INWORKS cohort have yielded 
relatively precise estimates of the linear excess relative risk (ERR) of all solid cancers (ERR 
per Gy =0.47; 90% CI: 0.18, 0.79) and leukemia, excluding chronic lymphocytic leukemia 
(ERR per Gy =2.96; 90% CI: 1.17, 5.21).9, 10
An important consideration in assessing radiation-related risk is how the risk is modified by 
temporal factors. The Life Span Study of atomic bomb survivors (LSS) provides a number 
of general observations on temporal patterns following acute exposure.11 First, exposure-
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related cancer risk has persisted over the follow-up period (1950-2003). Second, the risk is 
not immediately apparent following exposure but is observed after a latent period, which 
appears longer for solid cancers. Lastly, the ERR per unit dose for some cancers can 
significantly vary by temporal factors, such as time since exposure (TSE) or age at exposure 
(AE). The degree to which these observations hold true for protracted radiation exposure is 
poorly understood. To that end, the current study examined the effects of age at exposure 
and time since exposure on the cancer risk from protracted low-dose ionizing radiation 
exposure in the INWORKS cohort of nuclear workers.
Methods and Materials
Study cohort
The INWORKS cohort is described elsewhere.8 Briefly, the cohort comprised 308,297 
nuclear workers of both genders who were employed for one or more years in at least one of 
13 study facilities/companies and were individually monitored for occupational external 
exposure to ionizing radiation. The cohort was assembled using data obtained from: the 
Commissariat à l'Energie Atomique Civil, AREVA Nuclear Cycle, and Electricité de France 
in France 12; the National Registry for Radiation Workers in the UK 13; and the Hanford 
Site, the Savannah River Site, the Oak Ridge National Laboratory, the Idaho National 
Laboratory, and the Portsmouth Naval Shipyard in the USA.14 Vital status was ascertained 
between years 1946-2001, 1968-2004, and 1944-2005 for the UK, France, and USA 
subcohorts, respectively. Case status was defined by the underlying cause of death 
determined from death certificates and generally coded according to the 6th to 10th revision 
of the International Classification of Diseases (ICD) in effect at the time of death. The 
observation period began the later of: the date first monitored for radiation exposure; the 
start date of the applicable death registry; or one year after date first hired. The end of 
observation was on the earliest of the death date, date lost to follow-up, or the end of follow-
up.
This research was approved by the Institutional Review Board (IRB) of the National 
Institute for Occupational Safety and Health (NIOSH). As required by the French Data 
Protection Authority, workers in France were given the opportunity to refuse participation; 
however, none refused to participate. UK workers can also refuse participation in the NRRW 
and associated studies; however, less than 1% refused to participate. Based on its review, the 
NIOSH IRB waived requirements for informed consent of USA participants.
Outcomes of interest
Analyses were restricted to outcomes from the previous INWORKS studies (except for 
CLL) with 100 or more observed deaths and includes: all solid cancers, leukemia excluding 
chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid 
leukemia (CML), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and multiple 
myeloma (MM).9, 10 CLL was excluded because it lacked evidence of radiogenicity in the 
previous analysis. In addition, we examined lung cancer as the leading cause of cancer death 
(Table S1). It is acknowledged that all solid cancers and non-CLL leukemia comprise 
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heterogeneous groups of diseases with varying etiologies; however, both outcomes are 
frequently assessed because of their importance in radiation protection and risk assessment.
Exposure
Details on the exposure assessment methods are presented elsewhere.15, 16 Briefly, dose 
reconstruction methods were an extension of methods used in the previous IARC pooled 
study, whereby individual records of personal monitoring data were used to estimate annual 
doses over the course of employment of each worker. The majority of occupational radiation 
exposure was attributed to penetrating gamma and x-ray radiations of energies between 0.1 
and 3.0 mega-electron volt (MeV); however, some measurements of neutron exposures were 
also recorded. For photons, measurements were adjusted for exposure geometry, body 
attenuation, dosimeter response, dosimetry practices, and facility-specific exposure 
conditions to estimate the absorbed dose to the lung, active red bone marrow (RBM), and 
colon. RBM dose was used for all lymphohematopoietic outcomes. Colon dose, a common 
surrogate for “deep dose”, was used in analyses of all solid cancers combined. Neutron 
exposure was estimated as a time-dependent categorical variable of whether a worker had a 
positive recorded neutron dose, and if so, whether their neutron dose ever exceeded ten 
percent of their total external penetrating radiation dose. As in previous examinations, doses 
from internally deposited radionuclides were not quantified for this analysis. 9, 10
Statistical Methods
All analyses were conducted using SAS software.17 General relative risk models were fit 
under a nested case-control design using methods analogous to conditional logistic 
regression with age as the time scale as described by Langholz and Richardson.18 This 
approach allows for exact control of attained age as a confounder and time-dependent 
exposures are precisely calculated at the failure time of the case. Cumulative dose was 
calculated by summing annual organ doses from age at first exposure to attained age of the 
associated case (i.e., age at death of the case) minus any applied exposure lag period. For 
each death in each outcome, 200 controls were drawn from cohort risk sets by incidence 
density sampling.19 Sampling was necessary due to computational restrictions; however, 
sampling a sufficient number of controls has been shown to give unbiased, efficient 
results.20 Controls were matched to cases on: attained age, sex, and country in all models; 
birth year (10-year intervals), socioeconomic status (5 categories based on job titles or 
employment category: professional and technical, skilled non-manual, skilled manual, 
unskilled, and uncertain), neutron exposure, (3 categories) and employment duration (10-
year intervals) for all solid cancers and lung cancer; and calendar period (5-year intervals) 
for all lymphohematopoietic cancers.9, 10 Point estimates were expressed as the excess 
relative risk (ERR) per cumulative absorbed tissue dose in gray (Gy) for consistency with 
previous publications. In some cases, negative ERR per Gy estimates were below the 
boundary for relative risk (i.e., ERR < -1.0) because of linear extrapolation to a dose of one 
Gy. We present these artefactual results for consistency with previous results. Linear models 
allow estimates to be easily scaled to values typical to workplaces and within the boundary 
of relative risk.
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All modeling was conducted using the NLMIXED procedure. Models used a linear rate 
function, based on findings from previous studies and an examination of alternative 
(nonlinear) rate functions during model development. Modeling was conducted in six basic 
steps. First, we examined cumulative dose-mortality associations under a fixed exposure lag 
specified a priori: 2 year lag for leukemias and 10 year lag for all other cancers. The lag 
discounted exposures that occurred during the period immediately prior to attained age and 
serves as the ‘latent’ period. Second, we compared a range of lags (2-40 years in one year 
increments) using a grid search to find the lag that maximized the likelihood function (i.e., 
fitted lag). Third, we fit a piecewise constant model (i.e., time windows), with exposure 
accrued in windows of 2<10 (for leukemias and MM), 10<20, 20<30 and 30+ years prior to 
attained age to examine TSE effects. Fourth, we fit a cubic B-spline model to describe 
variation in ERR per Gy with TSE.21 The B-spline function used two evenly spaced knots 
and models were restricted to decrease to zero at 60 years prior to attained age. Fifth, time-
windows and B-splines were also used to assess variation in the ERR per Gy with AE. These 
models used age windows of <35, 35<50, and 50+ and a 2-year lag for hematopoietic 
cancers (leukemias and MM) and 10-years for all others. Thus, the estimate in the 35<50 
year window corresponds to the dose accrued between age 35 and 50 years. Finally, joint 
analysis was conducted using AE windows (<35, 35<50, and 50+) cross classified with TSE 
windows (2<10, 10<20, and 20+). Given the large number of parameters to be estimated, 
joint analyses were restricted to all solid cancers and non-CLL leukemia.
For consistency with previous studies, model estimates included 90% confidence intervals 
(CI). The CIs for all models except B-splines were likelihood-based. Likelihood-based CIs 
were computationally expensive for B-spline models; therefore, 90% Wald-based CIs were 
estimated. Likelihood-based confidence bounds that did not converge or were on the 
boundary of parameter space were annotated as ‘not calculable’ (NC). Model comparisons 
were made by likelihood ratio tests. Based on reviewer comments, we also examined effect 
modification by categories of attained age (<60, 60<80, and 80+ years) in fixed lag models 
as a means to validate proportional hazards. Other post hoc analyses combining exposure 
windows in AE analyses were conducted based on inspection of risk patterns in a priori 
models.
Results
The cohort was mostly male (87%). A large proportion was still alive (77%) at study end. 
Less than 2% of persons were lost to follow-up. Among 66,632 decedents, there were 
19,748 deaths identified having cancer as the underlying cause. The average age at first 
exposure was 31 years. About 83% of the study population had a positive recorded dose 
(Table 1). The radiation dose distribution was right-skewed, with mean and median 
cumulative colon doses through the end of follow-up for each worker of 17.4 mGy and 2.3 
mGy, respectively. We found no evidence of significant interaction between exposure and 
attained age for any outcome (Table S2).
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Time Since Exposure (TSE)
In comparing similar models, our estimates differed slightly from those in the previous 
studies. These differences were likely from the different statistical approaches used. 
Significant positive dose-response associations were evident in fixed lag models for all solid 
cancers (ERR per Gy =0.42; 90% CI: 0.13, 0.73), non-CLL leukemia (ERR per Gy =2.80; 
90% CI: 0.96, 5.10), and CML (ERR per Gy =11.17; 90% CI: 4.44, 21.26). Compared to 
fixed exposure lags, fitted lags decreased by 7-8 years for all solid cancers, lung cancer, and 
MM, but increased for leukemias (+3 to 17 years) and lymphomas (+8 to 17 years). 
However, none of these differences were statistically significant. These changes had little 
effect on the ERR per Gy for all solid cancers, lung cancer, CML, and MM. However, 
marked increases in the ERR per Gy were observed for non-CLL leukemia (67%), AML 
(183%), HL (221%), and NHL (210%) in fitted lag models compared to fixed lags. The most 
improved fit (p-value =0.09) was observed for non-CLL leukemia, where the ERR per Gy 
increased nearly two-fold using a 19 year lag (ERR per Gy =4.68; 90% CI: 1.26, 9.37) 
(Table 2).
Results from time series windows of TSE are shown in Table 3 and Table S3. TSE effects 
were more evident in CML (p-value=0.02), HL (p-value =0.11), and non-CLL leukemia (p-
value =0.17) compared to other outcomes, although only CML effects were statistically 
significant. The pattern in CML suggested two peak periods prior to attained age; one for 
exposures within 2-10 years (ERR per Gy =23.12; 90% CI: 5.57, 50.25) and another for 
exposures within 20<30 years (ERR per Gy =59.94; 90% CI: 29.18, 103.83). Sandwiched 
between these periods, the ERR per Gy was strongly attenuated (ERR per Gy =-28.84; 90% 
CI: NC, -5.30). Excess HL risk was observed only in the 20<30 year TSE window (ERR per 
Gy =29.16, 90% CI: NC, 75.55). Peak excess AML risk was associated with exposures in 
the 20<30 year window (ERR per Gy =5.62; 90% CI: -0.46, 14.02). The pattern in non-CLL 
excess risk reflected the combination of CML and AML patterns. Findings for all solid 
cancers and lung cancer suggested persistent excess risk over the first two periods followed 
by an absence of excess risk at 30+ years TSE. There were also indications of persistent 
excess risk of MM and NHL over TSE. The excess risk was greatest in the 20<30 year 
window for MM (ERR per Gy =3.97; 90% CI: NC, 11.89) and in the 30+ year window for 
NHL (ERR per Gy =1.86, 90% CI: -0.98, 5.31).
The findings from TSE B-spline models were in reasonable agreement with those in time 
series windows for all outcomes except HL (which did not converge) and CML (Figure 1 
and Figure S1). The wide variation in the CML piecewise model was far less evident in the 
B-spline model (Figure 1); however, the shape of the curve followed the general pattern 
suggested by time series windows.
Age at Exposure (AE)
Results from piecewise constant models are shown in Table 4 and Table S4. Statistically 
significant modification by AE was not observed in any outcome tested. Evidence of 
heterogeneity by AE was strongest for all solid cancers (p-value =0.086) and lung cancer (p-
value =0.093), where excess risk first appeared in the 35<50 year AE window and the ERR 
per Gy appeared consistent thereafter. Combining the last two age groups provided an ERR 
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per Gy estimate for all solid cancers of 0.66 (90% CI: 0.31, 1.03) for AE of 35 years or older 
(p-value = 0.03). Similar patterns were observed for lung cancer (ERR per Gy =0.85; 90% 
CI: 0.25, 1.55; p-value = 0.03) and to a lesser extent MM (ERR per Gy =2.23; 90% CI: 
-0.21, 5.56; p-value = 0.27). For AML, the ERR per Gy was greatest for exposure ages <35 
years (ERR per Gy =6.36; 90% CI: -0.35, 15.93), attenuated in the middle window, and then 
positive again in the 50 year or older age window (ERR per Gy =2.77; 90% CI: -1.76, 
10.07). The NHL excess risk appeared to decrease with increasing AE; the greatest ERR per 
Gy was observed for exposure ages 35 years or less (ERR per Gy =3.03; 90% CI: -1.38, 
8.47), although the estimate for exposure ages between 35-50 years was also positive (ERR 
per Gy =1.42; 90% CI: -1.17, 4.50). Combining these two age groups resulted in an ERR per 
Gy of 1.93 (90% CI: 0.04, 4.21; p-value = 0.13) for exposures at ages <50 years.
As in TSE analyses, the results from AE B-spline models were in reasonable agreement with 
the findings from time series windows, except for HL, which again did not converge (Figure 
1 and Figure S2).
Joint Analyses of AE and TSE Effects
The results of the joint analyses were largely consistent with separate TSE and AE analyses 
(Table 5 and Table S5). The ERR per Gy for solid cancers combined was largest for doses 
accrued at ages 35 to <50 years and 2 to <10 years prior to attained age; however, the most 
precise estimate (ERR per Gy =0.75; 90% CI: 0.03, 1.42) was obtained for exposures 
accrued 20 or more years prior to attained age and exposure ages 35 to <50 years. The 
combined temporal effect on the radiation risk of non-CLL leukemia was pronounced (p-
value =0.06) relative to that for solid cancers. The excess risk of non-CLL leukemia was 
largest for the cross-classification of the youngest exposure age group and fewest years prior 
to attained age. Also for non-CLL leukemia, significantly positive ERR per Gy estimates 
were observed in adjacent cells representing AE ages 35 years or older and TSE of 20 or 
more years. Of particular note is the pattern in which the excess risk diminished with 
increasing time-since-exposure for exposures received below age 35 years, while the 
opposite occurred for exposures received above age 50 years.
Discussion
Solid Cancers
Risk patterns for all solid cancers combined were largely similar to that of lung cancer, 
although lung cancer estimates appeared slightly less precise given fewer cases. Estimates 
for all solid cancers from fixed and fitted exposure lag models were compatible with the 
previous study 10 and the estimate for LSS men of working ages (ERR per Gy =0.37; 90% 
CI: 0.17, 0.60).12 As in the LSS, the all solid cancers excess risk persisted several decades 
after exposure. The evidence of lasting effects from ionizing radiation exposure underscores 
the importance of continued follow-up to gain full understanding of lifetime risks among 
nuclear workers.
The excess risk of all solid cancers and lung cancer appeared restricted to exposure ages 35 
years or greater. Evidence from other studies have also suggested associations between 
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radiation dose and lung cancer that are stronger at older exposure ages.7, 22-24 However, 
methods have varied among studies and differences in age-risk patterns between studies are 
apparent. These inconsistencies may result from underpowered analyses given low baseline 
cancer risk at young attained ages. Another possible explanation is temporal variation in 
confounding.24 There was no evidence of decreasing ERR by increasing AE, which is 
contrary to the 29% reduction per 10-year increase of AE recently found in the LSS.11 
However, LSS AE effects were largely influenced by relatively high risks among persons 
exposed before working ages; therefore, these findings may poorly translate to nuclear 
workers.
Hematopoietic cancers
We report a positive association between non-CLL leukemia and radiation exposure (under a 
2-year lag) that is compatible with an estimate for LSS males of working ages (ERR at 1 Sv 
= 2.63; 90% CI 1.50, 4.27). 12 Our leukemia risk estimates are similar to previous 
INWORKS estimates using Poisson regression, with significant risk also observed for non-
CLL leukemia (ERR per Gy = 2.96; 90% CI 1.17, 5.21) and CML (ERR per Gy = 10.45; 
90% CI 4.48, 19.65) in that study.9 Extending the lag period to 19 years under the fitted 
model markedly increased the magnitude of the non-CLL leukemia ERR per Gy estimate, 
suggesting late onset of leukemia risk. This late onset was most evident in AML, which was 
also best-fit to a lag period of 19 years. A similar pattern was suggested by Leuraud et al. 
(2015), who reported improved model fit and increased excess risk for non-CLL leukemia 
and AML using the alternative lag of 10 years.9 These findings were consistent with 
piecewise and B-spline models that showed peak non-CLL leukemia, AML and CML risks 
from exposures 20-30 years prior to attained age. Richardson et al. (2009) reported similar 
TSE patterns in the LSS, which can be described as rapidly increasing non-CLL leukemia 
excess risk within 10 years of exposure, followed by a long period absent of excess risk, and 
then a slight uptick in excess risk occurring 45 years after exposure that is observed in all-
leukemias and AML, but not in CML.25 However, these effects were greatest at early 
exposure ages and disappeared in survivors who were aged 30 or more years at time of the 
bombings. Late onset leukemia has not been reported in previous worker studies, although 
these studies may lack sufficient follow-up to observe late effects.
Significant heterogeneity was observed for CML risk by TSE in the piecewise model. In 
contrast to AML, increased excess CML risk appeared shortly after exposure (2-10 year) and 
again much later (20-30 years). The first peak is consistent with previous studies of nuclear 
workers that report early onset of leukemia excess risk.26-28 The onset of the second peak is 
consistent AML, again suggesting delayed effects. However, CML piecewise model 
estimates appear exaggerated compared to those from the B-spline Model (Table 3). Both 
opposing piecewise estimates, which together indicate the largest change in excess risk with 
TSE (between 10 and 30 years), lie outside of the B-spline model confidence interval 
(Figure 1). Overly large estimates may indicate model instability from sparse data, which 
can inflate estimates downward when the ERR estimate is below zero and upward when it is 
above zero.29 This may explain the differences observed between piecewise and B-spline 
models for CML, where the latter shows a smoothed effect. Cautious interpretation of CML 
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findings is recommended given the inconsistencies between these models, especially in the 
absence of confirmatory results from other studies.
AML excess risk was greatest in the earliest and latest exposure age groups, suggesting a U-
shaped AE effect. In the recent study of cancer incidence in the LSS, Hsu et al. (2013) found 
a non-monotone AML dependence on AE, whereby the ERR per Gy was lowest among 
survivors exposed around age 30 years compared to younger or older ages, and if exposed as 
an adult, the ERR per Gy increased with increasing attained age.30 Long latency in 
radiation-induced myelodysplastic syndromes (MDS) has also been found in the LSS.31, 32 
MDS is a hematologic disorder that is associated with an increased risk of developing AML. 
However, we note that information on MDS radiogenicity is sparse and findings are possibly 
affected by MDS diagnosis and disease classification that have varied over time; therefore, 
patterns in risk MDS risk remain unclear.
Direct evidence of an association between ionizing radiation exposure and MM is 
limited.7, 11, 14, 33-35 Ichimaru et al. (1982) reported increased MM incidence in the LSS 
followed through 1976 that was restricted to AE between 20 and 59 years; however, the 
excess was not apparent for bone marrow doses less than 0.5 Gy or TSE less than 20 
years.33 Significant excess MM mortality risk was first reported after extending follow-up 
through 1985 (ERR per Gy to bone marrow = 2.29; 90% CI: 0.67, 5.31).34 Subsequent LSS 
updates; however, failed to report significant excesses and point estimates were 
diminished.11, 30, 35, 36 Among overlapping occupational studies, both the 15-Country Study 
(ERR per Sv =6.5; 90% CI: NC, 20.6; n=83) and the recent study of USA nuclear workers 
(ERR per Gy of 3.9 (95% CI: 0.60, 9.5; n=188) reported positive ERR per Gy estimates for 
MM.7, 14 Our estimates from fitted and fixed lags were also positive but less so, and 
appeared reasonably compatible with most recent LSS estimates.11,30 Our analyses of 
temporal effects on MM risk, though imprecise, suggested risk persisted with TSE and was 
primarily restricted to exposure ages 35 years or more. These findings appear consistent with 
the previous case control-study of workers from four U.S. nuclear facilities, including three 
facilities currently studied. Wing et al., (2000) reported dose response associations for MM 
and ionizing radiation that increased in magnitude with exposure age.37
Lymphatic cancers
Previous epidemiology has provided only limited evidence of ionizing radiation exposure as 
a risk factor for NHL and no evidence of causing HL.38, 39 Our study also provides little 
evidence supporting a dose-response for lymphatic cancers. Overall, our ERR per Gy 
estimates under fixed and fitted lags were positive but highly imprecise for both cancers. 
Poor estimate precision should be expected for HL given so few cases, but there was a 
relatively large number of NHL cases available.
Our NHL estimate using a 10-year lag was compatible with, but slightly less than an 
estimate for LSS males who were aged 15-64 years at the time of the bombing (ERR per Gy 
=1.12; 90% CI: 0.26, 2.51).40 However, the preferred lag in our study was nearly 30 years 
prior to attained age, resulting in an increase in the ERR per Gy of about three-fold 
compared to the fixed lag estimate. Excess NHL risk was also observed for dose accrued at 
age 50 years or less; the estimate of the ERR per Gy in this age range gained statistical 
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significance. The long latent period observed for NHL mortality in our study was consistent 
with the LSS data, which showed that most of the excess risk in A-bomb survivors occurred 
35 years or more after irradiation.40 This extended latency may explain the lack of evidence 
of association in previous studies with comparably less observation time.
Study Limitations
As in all observational studies, our study has a number of noteworthy limitations. The 
primary limitation is low statistical power to detect significant effect modification by age 
and time since exposure. Of all the effects tested, only CML by TSE was statistically 
significant. Furthermore, estimates from complex models necessary to examine temporal 
effects may be particularly vulnerable to sparse data. Although the INWORKS cohort is 
large, with long follow-up and many observed cancers, the low average doses and 
concomitant low excess risk preclude making conclusive statements about temporal or age 
effect modification, for most outcomes.
Other limitations were discussed in detail in the preceding reports;9, 10 therefore, they are 
only briefly reintroduced in this report. First, information on exposures to neutrons and 
incorporated radionuclides was insufficient to quantify dose. However, excluding workers 
flagged for potential neutron exposures (13%) and internal contamination (17%) had only 
modest effects on point estimates in previous analyses.9, 10 Second, we lacked information 
on important risk factors, such as exposures to other occupational carcinogens (e.g., benzene 
and asbestos) and lifestyle factors (e.g., smoking habits, alcohol consumption, and diet) that 
may distort risk estimates. Yet previous estimates of the ERR for solid cancer with and 
without lung cancer did not appreciably differ; suggesting that strong confounding by 
smoking or asbestos exposure is unlikely.10 We observed significant temporal effects for 
CML, which has sparse evidence of an association with benzene exposure 41 or other 
exogenous risk factors aside from ionizing radiation exposure. Thus, although residual 
confounding cannot be ruled out, unmeasured risk factors are unlikely to fully explain our 
findings. Third, for some cancers, mortality may be a poor substitute for cancer incidence, 
and many non-occupational factors can strongly influence cancer survival. Fourth, our study 
involved several statistical tests; therefore, the potential for spurious results is increased. 
Nevertheless, similar results across multiple methods were observed for most outcomes, 
which is evidence against chance findings. Fifth, errors in ascertainment and exposure 
measurement are also unavoidable sources of information bias given that records quality, 
disease classification, and dosimetry methods have changed over the observation period. 
Lastly, we are mindful that we report modest associations that are most vulnerable to bias or 
that may have simply resulted from chance alone.
Although the TSE and AE cubic regression B-spline plots were restricted to best show the 
informative range, some plots give warnings of large instability in tail regions, as depicted 
by rapidly increasing confidence intervals. Estimates in tail areas of splines are prone to 
instability; 42 therefore, we caution against over interpretation of estimates in these areas.
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This study provides direct information on the effect of temporal modifiers of cancer 
mortality risk from occupational ionizing radiation exposure. Given its size, length of 
follow-up, and quality of exposure information, the INWORKS cohort is well-suited to 
study the relation between occupational exposure to ionizing radiation and cancer. Yet 
although considerable statistical power has been realized by INWORKS, estimates of 
temporal effects on radiation risk are still largely imprecise. Statistically significant temporal 
effect modification was observed only for CML by TSE, which points to generally modest 
temporal effects on the relatively weak association between low-dose ionizing radiation 
exposure and cancer.
In conclusion, we found temporal risk patterns that appeared to vary by cancer type; 
emphasizing the need for more tumor-specific analyses. We also found that the excess risk 
of certain cancers persisted over the entire observation period spanning several decades, 
which suggests additional follow-up is needed to fully describe lifetime risks. Finally, this 
study is among the first reporting late onset of exposure-related leukemia mortality in 
nuclear workers. These findings add to our understanding of cancer risk from protracted low 
dose rate exposure to ionizing radiation. Nevertheless, there are a number of study 
limitations that encourage cautious interpretation.
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We examine cancer mortality risk from occupational radiation exposure in the 
International Nuclear Workers Study (INWORKS) cohort, comprising over 300,000 
nuclear workers contributing over eight million person-years at risk. The current work 
assesses effects of age at exposure and time since exposure on linear excess relative risk 
estimates. This study is first to report late onset leukemia from protracted occupational 
radiation exposure. These findings add to our understanding of cancer risk from ionizing 
radiation.
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Excess relative risk (ERR) of chronic myeloid leukemia by: Panel A, time since exposure 
(TSE), Panel B, age at exposure (AE). Solid line, B-Spline models with 90% CI indicated by 
dashed line. Midpoints of piecewise windows, filled circles with 90% CI indicated by error 
bars. Small dash line, fixed lag estimate with 90% CI in grey field.
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Table 1
Characteristics of the INWORKS cohort
Characteristic France United Kingdom United States INWORKS
Workers 59,003 147,866 101,428 308,297
 With cumulative dose >0 42,206 130,373 84,587 257,166
Sex (%)
 Male 51,567 (87.4) 134,812 (91.2) 81,883 (80.7) 268,262 (87.0)
 Female 7,436 (12.6) 13,054 (8.8) 19,545 (19.3) 40,035 (13.0)
Year of Birth
 Average 1947 1944 1934 1941
 Range 1894-1975 1877-1983 1873-1973 1873-1983
Follow-up
 Calendar period 1968-2004 1946-2001 1944-2005 1944-2005
 Average duration (years) 25 23 33 27
 Total person-years 1,469,500 3,410,483 3,341,049 8,221,032
Vital status (%)
 Alive 52,565 (89.1) 118,775 (80.3) 65,573 (64.7) 236,913 (76.9)
 Deceased 6,310 (10.7) 25,307 (17.1) 35,015 (34.5) 66,632 (21.6)
 Emigrated or Lost to follow-up 128 (0.22) 3,784 (2.6) 840 (0.83) 4,752 (1.5)
Exposure
 Year of first exposure1
  Average 1977 1975 1966 1972
  Range 1950-2004 1946-1999 1932-2005 1932-2005
Duration (years)2
  Average 12 10 12 11
  Range 1-41 1-51 1-56 1-56
Age (years) at first exposurea
  Average 30 30 32 31
  5%-95% Range 21-45 18-52 19-51 18-51
Mean Dose (50th, 95th percentile)
  RBM mGy 11.6 (1.3, 58.9) 18.2 (2.6, 83.3) 15.2 (1.9, 80.5) 15.9 (2.1, 78.0)
  Colon mGy 12.7 (1.5, 63.8) 19.9 (2.9, 94.3) 16.7 (2.1, 88.2) 17.4 (2.3, 85.1)
  Lung mGy 12.6 (1.4, 64.1) 19.8 (2.9, 94.1) 16.6 (2.0, 87.7) 17.4 (2.3, 85.0)
1
First exposure is the first positive photon dose record.
2
Duration in years between first and last positive photon dose record before the end of follow-up.
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